- Home
- NERV vs RNXT Comparison
NERV vs RNXT Comparison
Compare NERV & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- RNXT
- Stock Information
- Founded
- NERV 2007
- RNXT 2012
- Country
- NERV United States
- RNXT United States
- Employees
- NERV N/A
- RNXT N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- RNXT Health Care
- Exchange
- NERV Nasdaq
- RNXT Nasdaq
- Market Cap
- NERV 18.3M
- RNXT 21.6M
- IPO Year
- NERV 2014
- RNXT 2021
- Fundamental
- Price
- NERV $2.20
- RNXT $1.09
- Analyst Decision
- NERV Hold
- RNXT Strong Buy
- Analyst Count
- NERV 1
- RNXT 3
- Target Price
- NERV $5.00
- RNXT $6.13
- AVG Volume (30 Days)
- NERV 25.3K
- RNXT 29.5K
- Earning Date
- NERV 11-05-2024
- RNXT 11-13-2024
- Dividend Yield
- NERV N/A
- RNXT N/A
- EPS Growth
- NERV N/A
- RNXT N/A
- EPS
- NERV N/A
- RNXT N/A
- Revenue
- NERV N/A
- RNXT N/A
- Revenue This Year
- NERV N/A
- RNXT N/A
- Revenue Next Year
- NERV N/A
- RNXT N/A
- P/E Ratio
- NERV N/A
- RNXT N/A
- Revenue Growth
- NERV N/A
- RNXT N/A
- 52 Week Low
- NERV $2.10
- RNXT $0.53
- 52 Week High
- NERV $13.49
- RNXT $2.35
- Technical
- Relative Strength Index (RSI)
- NERV 34.31
- RNXT 56.37
- Support Level
- NERV $2.26
- RNXT $1.04
- Resistance Level
- NERV $2.43
- RNXT $1.17
- Average True Range (ATR)
- NERV 0.16
- RNXT 0.08
- MACD
- NERV -0.01
- RNXT 0.01
- Stochastic Oscillator
- NERV 13.71
- RNXT 67.86
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.